<DOC>
	<DOCNO>NCT00140452</DOCNO>
	<brief_summary>The use Thalidomide patient ALS disease progression .</brief_summary>
	<brief_title>Phase II Study Using Thalidomide Treatment ALS</brief_title>
	<detailed_description>Phase II open label trial test efficacy thalidomide ALS set disease progression .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Clinically proven ALS Disease duration less equal 5 year ALSFRSR score equal great 30 Patients know deep venous thrombosis hyper coagulable state exclude Patients FVC le 80 %</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>ALS</keyword>
</DOC>